Pharmacokinetics and dosing regimen of aminosidine in the dog
โ Scribed by C. Belloli; G. Crescenzo; S. Carli; R. Villa; O. Sonzogni; G. Carelli; P. Ormas
- Publisher
- Springer Netherlands
- Year
- 1996
- Tongue
- English
- Weight
- 513 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0165-7380
No coin nor oath required. For personal study only.
โฆ Synopsis
The kinetic behaviour of the aminoglycoside aminosidine, given at 15 mg/kg intravenously, intramuscularly and subcutaneously, was studied in 5 dogs to determine the appropriate dosage schedule. The pharmacokinetic behaviour of aminosidine in dogs was similar to that in other species, except that it was eliminated more slowly (beta = 0.007 +/- 0.0003 min-1). Intramuscular and subcutaneous administration produced peak serum concentrations (Cmax[im] = 32 +/- 6.4 micrograms/ml; Cmax[ac] = 36 +/- 3.4 micrograms/ml) and times to peak concentration (Tmax = 60 min for both) that did not differ significantly; and neither compartmental nor non-compartmental analysis revealed any significant differences between any of the kinetic parameters obtained for these two extravenous routes of administration. Comparison of these results with previously published data suggests that aminosidine given once daily at 15 mg/kg would be as effective all, and safer than, the two or three daily administrations commonly employed in dogs.
๐ SIMILAR VOLUMES
A randomized, four-way cross-over design was used to assess the disposition of the cardioprotective agent, dexrazoxane, in four male beagle dogs following single I.V. administration of 10, 25, 50, and 100mgkg-l doses. Parent drug was quantified in plasma and urine with a validated high-pressure liqu